| 1 | potential | 42,375 |
| 2 | noncontraceptive | 28 |
| 3 | petrogenic | 8 |
| 4 | sinomenium | 7 |
| 5 | syllabic | 5 |
| 6 | time-variant | 4 |
| 7 | 25×25 | 3 |
| 8 | anti-avoidance | 3 |
| 9 | ciliar | 3 |
| 10 | midplane | 3 |
| 11 | typhlodromus | 3 |
| 12 | 'oxygen | 2 |
| 13 | antilithic | 2 |
| 14 | circuit-level | 2 |
| 15 | potential-independent | 2 |
| 16 | second-sphere | 2 |
| 17 | sjw/hypericin | 2 |
| 18 | socio- | 2 |
| 19 | worldly | 2 |
| 20 | 5,289 | 1 |
| 21 | 6.3±1.7mg | 1 |
| 22 | 7.0±0.3mg | 1 |
| 23 | abt-associated | 1 |
| 24 | age-15 | 1 |
| 25 | already-demonstrated | 1 |
| 26 | b-cell-related | 1 |
| 27 | bt-based | 1 |
| 28 | cardio-and | 1 |
| 29 | cardiorenal-protective | 1 |
| 30 | cch/m3r-induced | 1 |
| 31 | dkt-mediated | 1 |
| 32 | emotional/neurological | 1 |
| 33 | eof-related | 1 |
| 34 | faustian | 1 |
| 35 | gemfibrozil-pioglitazone | 1 |
| 36 | generally-claimed | 1 |
| 37 | gi-sparing | 1 |
| 38 | ho-1-mediated | 1 |
| 39 | hrp-based | 1 |
| 40 | hyper-activation-limiting | 1 |
| 41 | immunological- | 1 |
| 42 | kmu-3-mediated | 1 |
| 43 | label-friendly | 1 |
| 44 | now-documented | 1 |
| 45 | oft-enumerated | 1 |
| 46 | plenteous | 1 |
| 47 | resveratrol-elicited | 1 |
| 48 | rts-hsp70-induced | 1 |
| 49 | semi-competing | 1 |
| 50 | thsg-induced | 1 |
| 51 | time4u | 1 |
| 52 | ultimaster™ | 1 |
| 53 | updat | 1 |
| 54 | β-1,6-substituted | 1 |
| 1 | 'oxygen | 2 |
| 2 | 25×25 | 3 |
| 3 | 5,289 | 1 |
| 4 | 6.3±1.7mg | 1 |
| 5 | 7.0±0.3mg | 1 |
| 6 | abt-associated | 1 |
| 7 | age-15 | 1 |
| 8 | already-demonstrated | 1 |
| 9 | anti-avoidance | 3 |
| 10 | antilithic | 2 |
| 11 | b-cell-related | 1 |
| 12 | bt-based | 1 |
| 13 | cardio-and | 1 |
| 14 | cardiorenal-protective | 1 |
| 15 | cch/m3r-induced | 1 |
| 16 | ciliar | 3 |
| 17 | circuit-level | 2 |
| 18 | dkt-mediated | 1 |
| 19 | emotional/neurological | 1 |
| 20 | eof-related | 1 |
| 21 | faustian | 1 |
| 22 | gemfibrozil-pioglitazone | 1 |
| 23 | generally-claimed | 1 |
| 24 | gi-sparing | 1 |
| 25 | ho-1-mediated | 1 |
| 26 | hrp-based | 1 |
| 27 | hyper-activation-limiting | 1 |
| 28 | immunological- | 1 |
| 29 | kmu-3-mediated | 1 |
| 30 | label-friendly | 1 |
| 31 | midplane | 3 |
| 32 | noncontraceptive | 28 |
| 33 | now-documented | 1 |
| 34 | oft-enumerated | 1 |
| 35 | petrogenic | 8 |
| 36 | plenteous | 1 |
| 37 | potential | 42,375 |
| 38 | potential-independent | 2 |
| 39 | resveratrol-elicited | 1 |
| 40 | rts-hsp70-induced | 1 |
| 41 | second-sphere | 2 |
| 42 | semi-competing | 1 |
| 43 | sinomenium | 7 |
| 44 | sjw/hypericin | 2 |
| 45 | socio- | 2 |
| 46 | syllabic | 5 |
| 47 | thsg-induced | 1 |
| 48 | time-variant | 4 |
| 49 | time4u | 1 |
| 50 | typhlodromus | 3 |
| 51 | ultimaster™ | 1 |
| 52 | updat | 1 |
| 53 | worldly | 2 |
| 54 | β-1,6-substituted | 1 |
| 1 | immunological- | 1 |
| 2 | socio- | 2 |
| 3 | age-15 | 1 |
| 4 | 25×25 | 3 |
| 5 | 5,289 | 1 |
| 6 | syllabic | 5 |
| 7 | antilithic | 2 |
| 8 | petrogenic | 8 |
| 9 | rts-hsp70-induced | 1 |
| 10 | thsg-induced | 1 |
| 11 | cch/m3r-induced | 1 |
| 12 | generally-claimed | 1 |
| 13 | hrp-based | 1 |
| 14 | bt-based | 1 |
| 15 | abt-associated | 1 |
| 16 | ho-1-mediated | 1 |
| 17 | kmu-3-mediated | 1 |
| 18 | dkt-mediated | 1 |
| 19 | eof-related | 1 |
| 20 | b-cell-related | 1 |
| 21 | oft-enumerated | 1 |
| 22 | already-demonstrated | 1 |
| 23 | resveratrol-elicited | 1 |
| 24 | now-documented | 1 |
| 25 | β-1,6-substituted | 1 |
| 26 | cardio-and | 1 |
| 27 | anti-avoidance | 3 |
| 28 | midplane | 3 |
| 29 | gemfibrozil-pioglitazone | 1 |
| 30 | second-sphere | 2 |
| 31 | cardiorenal-protective | 1 |
| 32 | noncontraceptive | 28 |
| 33 | 7.0±0.3mg | 1 |
| 34 | 6.3±1.7mg | 1 |
| 35 | gi-sparing | 1 |
| 36 | semi-competing | 1 |
| 37 | hyper-activation-limiting | 1 |
| 38 | emotional/neurological | 1 |
| 39 | potential | 42,375 |
| 40 | circuit-level | 2 |
| 41 | sinomenium | 7 |
| 42 | faustian | 1 |
| 43 | 'oxygen | 2 |
| 44 | sjw/hypericin | 2 |
| 45 | ciliar | 3 |
| 46 | typhlodromus | 3 |
| 47 | plenteous | 1 |
| 48 | updat | 1 |
| 49 | time-variant | 4 |
| 50 | potential-independent | 2 |
| 51 | time4u | 1 |
| 52 | worldly | 2 |
| 53 | label-friendly | 1 |
| 54 | ultimaster™ | 1 |